1. A phase Ia/Ib study of novel anti‐ErbB3 monoclonal antibody, barecetamab (ISU104) in refractory solid cancers and monotherapy or in combination with cetuximab in recurrent or metastatic head and neck cancer
   Seyoung Seo et al, 2023, International Journal of Cancer CrossRef
2. First-Line Cetuximab Monotherapy in KRAS/NRAS/BRAF Mutation-Negative Colorectal Cancer Patients
   Vladimir M. Moiseyenko et al, 2018, Clinical Drug Investigation CrossRef
3. Switching anti-EGFR antibody re-sensitizes head and neck cancer patient following acquired resistance to cetuximab
   Arun Khattri et al, 2024, Cancer Gene Therapy CrossRef
4. Aberrant up-regulation of iNOS/NO system is correlated with an increased abundance of Foxp3+ cells and reduced effector/memory cell markers expression during colorectal cancer: immunomodulatory effects of cetuximab combined with chemotherapy
   Sarra Benkhelifa et al, 2019, Inflammopharmacology CrossRef